TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02517918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus combined with CP, MT and ZA
Description: Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).~Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established.
Study: NCT04156841

Intervention type: DIAGNOSTIC_TEST
Intervention: mapping agent
Description: according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.

Intervention type: DIAGNOSTIC_TEST
Intervention: mapping agent
Description: according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.

Intervention type: PROCEDURE
Intervention: neoadjuvant chemotherapy
Description: Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.

Intervention type: PROCEDURE
Intervention: neoadjuvant chemotherapy
Description: Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
Study: NCT00601224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social cognition and interaction training (SCIT)
Description: SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
Study: NCT02838927

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00871299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program and medication management
Description: The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
Study: NCT03590405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterus transplantation surgery and IVF
Description: IVF before surgery living donor uterus transplantation ET
Study: NCT03636074

Intervention type: PROCEDURE
Intervention: Hypothermia during Extracorporeal Circulation
Description: Normothermia during Extracorporeal Circulation

Intervention type: PROCEDURE
Intervention: Hypothermia during Extracorporeal Circulation
Description: Normothermia during Extracorporeal Circulation
Study: NCT03260946

Intervention type: OTHER
Intervention: Complementary medicine use
Description: The prevalence of complementary medicine use
Study: NCT02064673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Curcumin or placebo 500mg by mouth twice a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: Curcumin or placebo 500mg by mouth twice a day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo orally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo orally twice a day
Study: NCT04251052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Salpingectomy
Description: Undergo bilateral salpingectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Salpingectomy with Oophorectomy
Description: Undergo bilateral salpingo-oophorectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT01850732

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound of aorta
Study: NCT01572376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of autologous bone marrow stem cells after wound debridement.
Description: Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
Study: NCT04279392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid 5 mg/Bag 100 ml Inj
Description: Zoledronic acid infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline infusion
Study: NCT01164644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica montana
Description: Subjects will take twelve pills by mouth three times a day over four days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take twelve pills by mouth three times a day over four days.
Study: NCT01236365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 or 20 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin Placebo
Description: 10 or 20 mg daily
Study: NCT00602940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 12 treatments over 8 weeks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: 12 treatments over 8 weeks
Study: NCT02708264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Description: The cervical pessary is a silicone device that has been used to prevent SPTB
Study: NCT00641329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLONICEL (clonidine HCl sustained release)
Description: Flexible Dose (0.1 - 0.4 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT02190045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii-Fit exercises
Description: Wii-Fit exercises will be administered for 45 minutes 3 days of the week for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive remediation exercises
Description: Cognitive Remediation exercises will be administered for 45 minutes 3 days of the week for 8 weeks
Study: NCT03862001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LungCARE
Description: The LungCARE intervention involves patient and PCP components. The patient component consists of watching a short, educational video, answering questions about lung cancer screening preferences, and receiving a patient report and handout.~The PCP component consists of receiving a similar report (physician report) prior to the patient visit. This report is based on the patient's risk factors and lung cancer screening preferences. It contains additional information about documenting discussions related to risk, screening, and referrals in the electronic medical record system.
Study: NCT00700258

Intervention type: DRUG
Intervention: Temsirolimus
Description: Non-interventional study. Treatment decision already made before inclusion into the registry.

Intervention type: DRUG
Intervention: Temsirolimus
Description: Non-interventional study. Treatment decision already made before inclusion into the registry.

Intervention type: DRUG
Intervention: Sunitinib
Description: Non-interventional study. Treatment decision already made before inclusion into the registry.

Intervention type: DRUG
Intervention: Sunitinib
Description: Non-interventional study. Treatment decision already made before inclusion into the registry.

Intervention type: DRUG
Intervention: Axitinib
Description: Non-interventional study. Treatment decision already made before inclusion into the registry.
Study: NCT03237039

Intervention type: RADIATION
Group type: OTHER
Intervention: X-ray examination
Description: Radiological examination of frontal and lateral planes, simultaneously acquired with low dose X-ray system (EOS system, France) in one single exposition. The evaluation of the radiographic images will be performed by an orthopedic physician.Image processing will be performed by a biomedical engineer through sterEOS proprietary software and will provide the anatomical parameters needed to classify the sagittal profile.

Intervention type: OTHER
Group type: OTHER
Intervention: fall-risk assessment
Description: This evaluation will be performed after the radiographic scan, in the same day. The fall-risk assessment test will be performed by a biomedical engineer through OAK device (OAK, Khymeia, Italy). The OAK device integrates two force plates and sensory elastic straps applied to pelvis and limbs. This test, which takes approximately twenty minutes, accounts eight consecutive postural equilibrium exercises and provide the automatic detection of subject's postural parameters. At the end of the test, the fall-risk rating is automatically assigned.

Intervention type: OTHER
Group type: OTHER
Intervention: gait cycle analysis
Description: This assessment will be performed in the same session of fall-risk evaluation. The gait cycle analysis, which takes approximately forty minutes, will be executed by a biomedical engineer. Adhesive passive reflective markers will be placed on the skin according to a protocol suitable to characterize the alignment of lower limbs and trunk. The markers trajectories during walk will be recorded by an eight cameras optoelectronic system (BTS smart-D, Italy). A force platform (Kistler, Switzerland) placed in the middle of the pathway will detect the forces exchanged with the ground. The data analysis will provide the kinematic and kinetic descriptive parameters of gait cycle.
Study: NCT03925545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluidVision AIOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluidVision AIOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ monofocal IOL
Description: Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Standard cataract extraction with phacoemulsification

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Standard cataract extraction with phacoemulsification
Study: NCT01147601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical 0.5% Timolol
Description: topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: Control (placebo) group
Study: NCT04073459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Sabin IPV-Hib
Description: Intramuscular injection into the anterolateral area of the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Sabin IPV-Hib
Description: Intramuscular injection into the anterolateral area of the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Sabin IPV-Hib
Description: Intramuscular injection into the anterolateral area of the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentavalent vaccine and Salk IPV
Description: Intramuscular injection into anterolateral area of the thigh
Study: NCT03206710

Intervention type: OTHER
Intervention: No current intervention
Description: This is a follow-up of two randomized trials. No active intervention is being given in the follow-up

Intervention type: OTHER
Intervention: No current intervention
Description: This is a follow-up of two randomized trials. No active intervention is being given in the follow-up

Intervention type: OTHER
Intervention: No current intervention
Description: This is a follow-up of two randomized trials. No active intervention is being given in the follow-up
Study: NCT02782624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 5 days of treatment with 5 mg BI 10773 bid until steady state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 5 days of treatment with 10 mg BI 10773 qd until steady state
Study: NCT01496040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2/4.hRPE65
Description: One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP.
Study: NCT01523964

Intervention type: OTHER
Group type: OTHER
Intervention: Testing with EIM

Intervention type: OTHER
Group type: OTHER
Intervention: Testing with EIM

Intervention type: OTHER
Group type: OTHER
Intervention: Testing with EIM

Intervention type: OTHER
Group type: OTHER
Intervention: Testing with EIM
Study: NCT04251052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal Ultrasound
Description: Undergo transvaginal ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal Ultrasound
Description: Undergo transvaginal ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo pelvic ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Imaging
Description: Undergo pelvic ultrasound
Study: NCT01364051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study: NCT03054519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will be prescribed up to 2,000 mgs daily of metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
Study: NCT03655340

Intervention type: DRUG
Intervention: Alprolix
Description: Extended half-life factor IX product

Intervention type: DRUG
Intervention: Alprolix
Description: Extended half-life factor IX product
Study: NCT04539496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: * 20-560 mg QD, oral~* 240-480 mg BID, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287;Letrozole;Anastrozole;Fulvestrant
Description: XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287
Description: 480 mg BID, oral
Study: NCT02588690

Intervention type: PROCEDURE
Intervention: Fingerstick cholesterol test
Description: A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.

Intervention type: OTHER
Intervention: Atherosclerosis Cardiovascular Disease Risk assessment
Description: This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol \<190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status.

Intervention type: PROCEDURE
Intervention: Blood pressure measurement
Description: Blood pressure measurement
Study: NCT00207155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
Study: NCT01874639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard bipolar coagulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Aquamantys® probe for liver hemostasis
Study: NCT04038359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Phosphoinositide 3-kinase (PI3K) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Phosphoinositide 3-kinase (PI3K) inhibitor
Study: NCT01766609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study: NCT01281618

Intervention type: PROCEDURE
Intervention: 24 hour pH study and upper endoscopy (EGD)
Description: All subjects enrolled will undergo 24 hour pH followed by EGD.
Study: NCT04332822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-pola-mini-CHP
Description: * Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~* Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~* Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~* Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~* Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mini-CHOP
Description: * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
Study: NCT02381600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Experimental :~1. Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~2. Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~3. At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.
Study: NCT03893071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl-β-cyclodextrin
Description: HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
Study: NCT02955589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000
Description: Oral, twice weekly
Study: NCT02738801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690 600 mg QD
Description: GLPG1690 capsules, administered at a dose of 600 mg, orally QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo QD
Description: Matching placebo capsules, administered orally QD
Study: NCT02971917

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chest x-ray image acquisition
Description: Obtain a digital X-ray chest image of the patient

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Creation of TRUVIEW ART applied image
Description: Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.~Outcome: 2 versions of chest image~1. Original Chest X-ray (w/o TRUVIEW ART)~2. TRUVIEW ART applied image

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Comparison of TRUVIEW ART image with original image
Description: Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
Study: NCT03207126

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound guided biopsy
Description: For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
Study: NCT04069559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To develop nursing students' attitudes towards refugees program which based on contact hypothesis.
Description: In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
Study: NCT01025908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportative psychotherapy
Description: Supportative psychotherapy